Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: May 2010

Chapter 5 - Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study

References

1. NormanRM, MallaAK, McLeanT, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica 2000;102:303–9.
2. PriebeS. Social outcomes in schizophrenia. British Journal of Psychiatry 2007;191:s15–s20.
3. RosenheckRA, StroupS, KeefeR, et al. Measuring outcome priorities and incorporating preferences in mental health status assessment of people with schizophrenia. British Journal of Psychiatry 2005;187:529–36.
4. LambertM and NaberD. Current issues in schizophrenia: Overview of patient acceptability, functioning and quality of life. CNS Drugs 2004;18(Suppl):5–17.
5. KarowA and NaberD. Subjective well-being and quality of life under antipsychotic treatment. Psychopharmacology 2002;162:3–10.
6. AwadAG and VorugantiLNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877–93.
7. HeinrichsDW, HanlonTE, CarpenterWT Jr.The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–98.
8. MeltzerHY, BurnettS, BastaniB and RamirezLF. Effects of six months of clozapine treatment on quality of life of chronic schizophrenic patients. Hospital & Community Psychiatry 1990;41:892–7.
9. EssockSM, HargreavesWA, CovellNH, et al. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacology Bulletin 1996;32:683–97.
10. RosenheckR, CramerJ, XuW, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs cooperative study group on clozapine in refractory schizophrenia. New England Journal of Medicine 1997;337:809–15.
11. TranPV, HamiltonSH, KuntzAJ, et al. Double-blind comparison of olanzapine vs. risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997;17:407–18.
12. HamiltonSH, RevickiDA, GendusoLA, et al. Olanzapine vs. placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41–9.
13. JonesPB, BarnesTRE, DaviesL, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)Archives of General Psychiatry 2006;63:1079–87.
14. SwartzMS, PerkinsDO, StroupTS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE Study. American Journal of Psychiatry 2007;164:428–36.
15. StroupTS, McEvoyJP, SwartzMS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003;29:15–31.
16. SwartzMS, PerkinsDO, StroupTS, et al. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophrenia Bulletin 2003;29:33–43.
17. DavisSM, KochGG, DavisCE, et al. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29:73–80.
18. KeefeRS, MohsRC, BilderRM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophrenia Bulletin 2003;29:45–55.
19. LiebermanJA, StroupTS, McEvoyJP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
20. StroupTS, LiebermanJA, McEvoyJP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611–22.
21. McEvoyJP, LiebermanJA, StroupTS, et al. Effectiveness of clozapine, quetiapine and risperidone in patients with chronic schizophrenia who failed prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;153:600–10.
22. SwartzMS, WagnerHR, SwansonJW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 2006;194:164–72.
23. SwartzMS, WagnerHR, SwansonJW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE Study. Psychiatric Services 2006;57:1110–6.
24. KeefeRS, BilderRM, HarveyPD, et al. Baseline neurocognitive deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology 2006;4:1–14.
25. KeefeRS, BilderRM, HarveyPD, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia. Archives of General Psychiatry 2007;64:633–47.
26. RosenheckR, LeslieD, SindelarJ, et al. Cost-effectiveness of first and second generation antipsychotics in the treatment of chronic schizophrenia. American Journal of Psychiatry 2006;163:2080–9.
27. TracyK, AdlerLA, RotrosenJ, et al. Interrater reliability issues in multicenter trials. Part I: Theoretical concepts and operational procedures in VA Cooperative Study #394. Psychopharmacology Bulletin 1997;33:53–57.
28. KaySR, FiszbeinA and OplerLA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261–76.
29. GuyW. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No. ADM 76–338). Rockville, MD: U.S. Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. pp 218–22.
30. DrakeRE, OsherFC, NoordsyDL, et al. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57–67.
31. AddingtonD, AddingtonJ, Maticka-TyndaleE, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 1992;6:201–8.
32. HoganT, AwadAG and EastwoodR.A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 1983;13:177–83.
33. WareJ Jr, KosinskiM and KellerSD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care 1996;34:220–33.
34. HochbergY. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–802.
35. ResnickSG, RosenheckRA, CaniveJ, et al. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research 2008;35:215–25.
36. TuunainenA, WahlbeckK and GilbodySM. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomised trials. Schizophrenia Research 2002;56:1–10.
37. WahlbeckK, CheineM and EssaliMA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000;2:CD000059.
38. JonesPB, BarnesTR, DaviesL, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079–87.
39. PinikahanaJ, HappellB, HopeJ, et al. Quality of life in schizophrenia: A review of the literature from 1995 to 2000. International Journal of Mental Health Nursing 2002;11:103–11.
40. SiegelSJ, IraniF, BrensingerCM, et al. Prognostic variables at intake and long-term level of function in schizophrenia. American Journal of Psychiatry 2006;163:433–41.
41. HafnerH. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 2):17–54.
42. CarterCS. Understanding the glass ceiling for functional outcome in schizophreniaAm J Psychiatry 2006;163:356–358.
43. CarpenterWT Jr. Targeting schizophrenia research to patient outcomes. American Journal of Psychiatry 2006;163:353–5.
44. LehmanAF, KreyenbuhlJ, BuchananRW, et al. The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin 2004;30:193–217.
45. LehmanAF, LiebermanJA, DixonLB, et al. American Psychiatric Association. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161(Suppl):1–56.